Retrospective analysis identifies systemic inflammatory markers influencing survival in metastatic castration-resistant prostate cancer, suggesting clinical relevance.
Objective: To investigate the prognostic value of systemic inflammatory markers (SIM)—namely neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ra-tio (PLR)—on survival outcomes and treatment response in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving abiraterone (ABI) or enzalu-tamide (ENZA) therapy. Methods: This two-center retrospective observational study analyzed clinical data of 106 patients diagnosed with mCRPC. The cut-off values for NLR and PLR were deter-mined as 2.83 and 156, respectively. Their effects on progression-free survival (PFS) and overall survival (OS) were evaluated using Kaplan-Meier and Cox regression analyses. Changes in SIM before and after ABI/ENZA treatment were assessed using the Wilcoxon signed-rank test. Results: Lower NLR (≤2.83) and PLR (≤156) levels were significantly associated with longer PFS and OS. In multivariate analysis, only high PLR emerged as an independent adverse prognostic factor for OS (HR: 2.01; p=0.026). Treatment response was an inde-pendent predictor of PFS. No significant changes were observed in MPV, PDW, or P-LCR levels after treatment. Conclusion: SIM such as NLR and especially PLR may serve as practical and accessible tools for predicting survival in mCRPC patients. However, further prospective studies are warranted.
No takes yet. Share an insight, caveat, or question.
Muğlu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: